• Read also: LIVE | The latest developments on COVID-19
The multinational pharmaceutical company submitted its request in the United States on October 7 and in Europe on Friday October 15. According to the “New York Times”, the American health authorities could decide the question at the beginning of November.
The European Medicines Agency (EMA) opened the case on Monday.
“Health Canada will only authorize the use of the Comirnaty vaccine if the independent and comprehensive scientific review of all of the data submitted confirms that the benefits of the vaccine outweigh the risks to this group,” the report said. Federal Ministry in a press release in the afternoon.
It was pointed out that Pfizer-BioNTech is currently conducting studies to develop a version of its vaccine for children under five.
As of October 15, Canada had recorded 342,495 cases among those 19 and under, representing 20.6% of total cases.